Indivior announces restructuring charges of $39-$50 million as part of Indivior Action Agenda

Indivior Pharmaceuticals, Inc.

Headcount reductions expected to incur pre-tax severance charges of approximately $16 to $19 million in Q3 2025.
Real estate consolidation and exit costs estimated at $15 to $22 million pre-tax, including leasehold improvements and asset write-downs.
Consulting, legal, and tax planning expenses of about $8 to $9 million pre-tax, recognized in Q3 2025.
Company is exploring strategic alternatives for OPVEE and its non-U.S. business, which could result in further one-time costs.
Restructuring charges will be excluded from non-GAAP financial measures, consistent with reporting practices.

item 2.05

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.